The mechanical properties of human alar and transverse ligaments at slow and fast extension rates.
Manohar M Panjabi, Joseph J Crisco, Christine Lydon...
https://pubmed.ncbi.nlm.nih.gov/11415778/Actively Recruiting
Led by Regenexx, LLC · Updated on 2025-04-06
80
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are evaluating a new approach to treat injuries of the alar, accessory, and transverse ligaments in patients with craniocervical junction CCJ instability. This study aims to assess the safety and effectiveness of using an anterior approach through the posterior oropharynx combined with bone marrow concentrate therapy. The trial is a single-center, randomized, controlled study that compares two bone marrow concentrate treatments to two sham procedures in patients suffering from symptoms related to CCJ instability, including headaches and dizziness. Participants in the treatment group will undergo bone marrow aspiration from the posterior iliac crest to prepare platelet rich plasma and platelet lysate mixed with bone marrow cells. Under anesthesia, this mixture will be injected into the injured ligaments using fluoroscopy and endoscopic guidance through the posterior oropharynx. Patients will also receive injections to upper cervical ligaments and facets. The control group will receive similar bone marrow aspiration but will undergo sham injections designed to mimic the procedure without the active treatment. Both groups will receive two procedures spaced three months apart. Throughout the study, patients will be assessed using clinical outcome questionnaires and digital motion X-rays at three months following the second procedure. Outcomes include changes in headache impact, neck disability, pain levels, and physical function. Safety will also be monitored through adverse event tracking for six months after treatment. Control participants may opt to receive the active treatment after the initial evaluation period. The total study duration extends up to 2030, with ongoing monitoring and evaluation.
CONDITIONS
Use of Bone Marrow Concentrate for Treatment of Alar, Accessory, and Transverse Ligament Injuries
E
Ehren R Dodson, PhD
N
Neven Steinmetz, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Regenexx, LLC
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Bone Marrow Concentrate Injection | Sham Control Procedure |
|---|---|---|
| What it is | Fluoroscopy‑ and endoscopy‑guided injection of autologous bone marrow concentrate into the alar, accessory, and transverse ligaments of the upper cervical spine using an anterior approach through the posterior oropharynx, administered twice, three months apart | Sham procedure involving small skin punctures to posterior oropharynx and back of the neck to mimic injections, under anesthesia, administered twice, three months apart |
| Role in trial | Investigational therapeutic procedure administered as one of the two crossover conditions | Control condition mimicking procedure without active bone marrow injection |
| Primary use | To treat craniocervical junction ligament injuries and reduce headache and disability | To serve as placebo‑like comparator for evaluating effects of the investigational injection |
| How it is given or performed | Autologous bone marrow concentrate is injected under sedation, under fluoroscopy and endoscopy guidance, via an anterior approach through the oropharynx, targeting upper cervical ligaments, given twice three months apart | Under sedation, small skin punctures are made to the oropharynx area and neck to mimic injection without delivery of any therapeutic agent, twice three months apart |
| Evidence status | No published randomized controlled results yet; the study is ongoing to evaluate effects on headache and neck disability | As control condition, efficacy relative to active injection is not established |
| Important risks | Potential risks include procedural complication from injection under anesthesia and fluoroscopy in a sensitive cervical region; specific safety profile not yet established | Risks include anesthesia and minor local tissue puncture; risks likely lower than the active intervention but not formally defined |
| Important limitations | Study has no long‑term efficacy data yet; crossover design may carry carry‑over effects between conditions | Sham may not fully blind participants or clinicians to differences; crossover timing may influence subjective outcome reporting |
| Patient impact | Impact on headache severity and neck disability remains to be determined by this trial | Effect on patient symptoms relative to active injection is not yet known |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person) for eligibility assessment
Duration - Approximately 3 months between the 2 procedures
Participants receive two treatment procedures 3 months apart. Each procedure involves bone marrow aspiration followed by injections under anesthesia targeting the upper cervical ligaments using an anterior approach through the posterior oropharynx. Participants randomized to the sham group receive similar bone marrow aspiration and sham injections to maintain blinding.
2 treatment visits under anesthesia spaced 3 months apart
Duration - 3 months after the 2nd procedure
Participants are evaluated 3 months after the second procedure using clinical outcome questionnaires and digital motion x-ray to assess effectiveness and safety. Control participants may crossover to treatment after unblinding at this time.
1 follow-up visit at 3 months post second procedure
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Manohar M Panjabi, Joseph J Crisco, Christine Lydon...
https://pubmed.ncbi.nlm.nih.gov/11415778/Christopher J Centeno, James Elliott, Whitney L Elkins...
https://pubmed.ncbi.nlm.nih.gov/16850045/A Rajwanshi, M Rohilla, P Singh
https://pubmed.ncbi.nlm.nih.gov/27489015/Christopher J Centeno, John Pitts, Hasan Al-Sayegh...
https://pubmed.ncbi.nlm.nih.gov/26261424/Regenexx, LLC
Lead Sponsor